There are currently 818 clinical trials in Detroit, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including Henry Ford Hospital, Henry Ford Health System, Barbara Ann Karmanos Cancer Institute and Karmanos Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
PREVENT ALL ALS Study
NCT06581861
Recruiting
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is begin funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The cl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Henry Ford Health, Detroit, Michigan
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
NCT03547973
Recruiting
The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Metastatic Urothelial Cancer
Register for Updates
ASSESS ALL ALS Study
NCT06578195
Recruiting
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The cl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Henry Ford Health, Detroit, Michigan
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment
NCT04118387
Recruiting
Central sleep apnea (CSA) is common in patients with heart failure and those using opioid analgesics. Unfortunately, effective treatment of central apnea remains elusive, pressure therapy given the modest efficiency of positive airway pressure therapy. The focus of this proposal is to identify mechanistic pathways to guide future therapeutic interventions for central sleep apnea based on the strong premise that multi-modality therapy will normalize respiration and hence mitigate adverse long-ter... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan
Conditions: Sleep Disordered Breathing, Able Bodied
Register for Updates
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
NCT04471727
Recruiting
This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig with I-DXd in participants with advanced cancers associated with expression of Delta-like Canonical Notch Ligand 3 (DLL3).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Karmanos Cancer Center, Detroit, Michigan
Conditions: Small-cell Lung Cancer, Neuroendocrine Carcinoma
Register for Updates
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
NCT04954859
Recruiting
This is a global multi-center, long-term follow-up study to assess durability of efficacy, as measured by maintenance of treatment response from the parent study, in participants who participated in a previous bepirovirsen study and achieved a complete or partial response. Eligible participants will be enrolled in this study after completing the end of study (EoS) visit in the respective parent bepirovirsen studies (studies B-Clear \[209668: NCT04449029\], B-Together \[209348: NCT04676724\], B-F... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: GSK Investigational Site, Detroit, Michigan
Conditions: Hepatitis B
Register for Updates
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
NCT05318573
Recruiting
To confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle, for treatment of advanced urothelial and non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit, Michigan
Conditions: Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer
Register for Updates
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study
NCT05639543
Recruiting
The purpose of this trial is to assess dose related safety, efficacy, and pharmacokinetics (PK) of INT-787 in participants with severe alcohol-associated hepatitis (sAH).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/09/2025
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Alcohol Associated Hepatitis
Register for Updates
CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)
NCT05897632
Recruiting
The goal of this study is to determine if rapid outpatient evaluation vs hospitalization management is the best strategy (based on patient-centered measures and safe, equitable, and efficient resource use) for evaluating patients with acute chest pain who are at moderate risk for acute coronary syndrome (ACS). Patients will be randomized in the Emergency Department to either an outpatient evaluation (CARE-CP) or hospitalization evaluation for their symptoms.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/09/2025
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: Chest Pain
Register for Updates
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
NCT06507306
Recruiting
The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2025
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Solid Tumor, Adult
Register for Updates
FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
NCT05135091
Recruiting
This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), is safe (frequency of adverse events) and effective (seizure frequency). NRTX-1001 comprises human interneurons that secrete a neurotransmitter, gamma-aminobutyric acid (GABA).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/03/2025
Locations: Wayne State University/Detroit Medical Center Comprehensive Epilepsy Program, Detroit, Michigan
Conditions: Mesial Temporal Lobe Epilepsy
Register for Updates
Prospective Clinical Registry Evaluating Contemporary MANTA Outcomes
NCT05936996
Recruiting
This is an observational study designed to evaluate the safety and clinical outcomes of the MANTA® Vascular Closure Device (VCD) (the MANTA® Device) in TAVR procedures. The study will enroll participants who are undergoing a TAVR procedure. The purpose of this study is to examine and collect data on outcomes of contemporary MANTA® large bore closure in standard of care (SOC) TAVR procedures with on-label use of the MANTA® device including appropriate patient selection and proper vascular access. Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/03/2025
Locations: Henry Ford Health, Detroit, Michigan
Conditions: Femoral Arteriotomy Closure
Register for Updates